Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Durvalumab +1 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Montvale, New Jersey
This trial will investigate if switching from durvalumab to sotorasib when minimal residual disease is detected is a better treatment for advanced lung cancer compared to staying on durvalumab.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.